Evidence map›Paper›PMID 32086583›Full record

ArticleEuropean radiology2020

A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma.

Lin Lu, Deling Wang, Lili Wang, Linning E, Pingzhen Guo, Zhiming Li, Jin Xiang, Hao Yang, Hui Li, Shaohan Yin and 3 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Lin LuDepartment of Radiology, Columbia University Medical Center, 710 West 168th Street, B26, New York, NY, 10032, USA.
Deling WangDepartment of Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Lili WangDepartment of Molecular Pathology, the Affiliated Hospital of Qingdao University, Qingdao University, Wutaishan Road 1677, Qingdao, 266000, Shandong, People's Republic of China.
Linning EDepartment of Radiology, Shanxi BETHUNE Hospital, 99 Longcheng Street, Taiyuan, 030032, Shanxi, People's Republic of China.
Pingzhen GuoDepartment of Radiology, Columbia University Medical Center, 710 West 168th Street, B26, New York, NY, 10032, USA.
Zhiming LiDepartment of Radiology, the Affiliated Hospital of Qingdao University, Qingdao University, Wutaishan Road 1677, Qingdao, 266000, Shandong, People's Republic of China.
Jin XiangDepartment of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Hao YangDepartment of Radiology, Columbia University Medical Center, 710 West 168th Street, B26, New York, NY, 10032, USA.
Hui LiDepartment of Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Shaohan YinDepartment of Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Lawrence H SchwartzDepartment of Radiology, Columbia University Medical Center, 710 West 168th Street, B26, New York, NY, 10032, USA.
Chuanmiao XieDepartment of Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China. xchuanm@sysucc.org.cn.
Binsheng ZhaoDepartment of Radiology, Columbia University Medical Center, 710 West 168th Street, B26, New York, NY, 10032, USA. bz2166@cumc.columbia.edu.
Columbia University Irving Medical Center · USSun Yat-sen University · CNQingdao University · CNShanxi Academy of Medical Sciences · CNSun Yat-sen University Cancer Center · CN

Funding

Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung CancerU01CA225431 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHWARTZ, LAWRENCE H, ZHAO, BINSHENG · 2018 to 2022
$3.1M
Ministry of Science and Technology of People's Republic of China PT07092001NCI NIH HHS U01 CA225431
6 · The paper itself

Abstract

objectivesClassification of histologic subgroups has significant prognostic value for lung adenocarcinoma patients who undergo surgical resection. However, clinical histopathology assessment is generally performed on only a small portion of the overall tumor from biopsy or surgery. Our objective is to identify a noninvasive quantitative imaging biomarker (QIB) for the classification of histologic subgroups in lung adenocarcinoma patients.

methodsWe retrospectively collected and reviewed 1313 CT scans of patients with resected lung adenocarcinomas from two geographically distant institutions who were seen between January 2014 and October 2017. Three study cohorts, the training, internal validation, and external validation cohorts, were created, within which lung adenocarcinomas were divided into two disease-free-survival (DFS)-associated histologic subgroups, the mid/poor and good DFS groups. A comprehensive machine learning- and deep learning-based analytical system was adopted to identify reproducible QIBs and help to understand QIBs' significance.

resultsIntensity-Skewness, a QIB quantifying tumor density distribution, was identified as the optimal biomarker for predicting histologic subgroups. Intensity-Skewness achieved high AUCs (95% CI) of 0.849(0.813,0.881), 0.820(0.781,0.856) and 0.863(0.827,0.895) on the training, internal validation, and external validation cohorts, respectively. A criterion of Intensity-Skewness ≤ 1.5, which indicated high tumor density, showed high specificity of 96% (sensitivity 46%) and 99% (sensitivity 53%) on predicting the mid/poor DFS group in the training and external validation cohorts, respectively.

conclusionsA QIB derived from routinely acquired CT was able to predict lung adenocarcinoma histologic subgroups, providing a noninvasive method that could potentially benefit personalized treatment decision-making for lung cancer patients. KEY POINTS: • A noninvasive imaging biomarker, Intensity-Skewness, which described the distortion of pixel-intensity distribution within lesions on CT images, was identified as a biomarker to predict disease-free-survival-associated histologic subgroups in lung adenocarcinoma. • An Intensity-Skewness of ≤ 1.5 has high specificity in predicting the mid/poor disease-free survival histologic patient group in both the training cohort and the external validation cohort. • The Intensity-Skewness is a feature that can be automatically computed with high reproducibility and robustness.

Indexed as

Adenocarcinoma of LungAgedArea Under CurveBiopsyCohort StudiesDeep LearningDisease-Free SurvivalFemaleHumansLung NeoplasmsMachine LearningMaleMiddle AgedPrognosisReproducibility of ResultsRetrospective StudiesAdenocarcinoma of lungDeep learningHistological types of neoplasmsMachine learningTomography, X-ray computed

Identifiers

PMID32086583
PMCPMC9039366
OpenAlexW3007192987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.